Gliomas and ependymomas appear to reuse developmental hierarchies, progenitor states, and neural-circuit signals that shape tumor heterogeneity and treatment response, although many proposed therapeutic vulnerabilities remain supported primarily by preclinical evidence.

Researchers identified a transfer RNA, tRNA¹Arg(UCU), that appears to regulate androgen receptor dependence in prostate cancer. Preclinical studies suggest manipulating this pathway may influence treatment sensitivity and the development of drug-resistant disease states.

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

A patient with advanced follicular lymphoma described a prolonged diagnostic journey marked by evolving symptoms, initial alternative diagnoses, urgent treatment initiation, and the psychological challenges that continued long after active therapy began.

Researchers identified a previously unrecognized B7-H3-driven pathway that promotes immune suppression in castration-resistant prostate cancer. Preclinical findings suggest dual targeting of B7-H3 and MEK signaling altered the tumor microenvironment and improved antitumor activity in experimental models.